Verseon Developing Oral Treatment For Hereditary Angioedema

Published: Sep 26, 2017

  • Drug candidates show good exposure suitable for oral dosing
  • Reduced swelling observed in the standard preclinical disease model for HAE

FREEMONT, Calif.--(BUSINESS WIRE)--Verseon has announced the launch of a drug program developing oral treatments for hereditary angioedema (HAE), a rare, life-threatening genetic disease. In their interim report published yesterday, the Company presented data from a well-established HAE disease model which demonstrate the efficacy of their plasma kallikrein inhibitors in reducing swelling.

HAE is a rare genetic condition affecting approximately 1 in every 50,000 people. The disease is caused by low levels or improper function of C1 inhibitor, a serine protease inhibitor needed to regulate vasodilation and edema. As a result, HAE patients suffer from recurring episodes of severe swelling (edema), which can affect the face, extremities, intestinal tract, and airways. Upper airway edema is considered especially dangerous and can even be life-threatening.

An oral therapeutic would be a life-changing development for HAE patients who currently rely on treatments administered via intravenous or subcutaneous injections. Verseon is building on expertise established in its diabetic macular edema program to develop small-molecule plasma kallikrein inhibitors suitable for oral dosing. Plasma kallikrein is an established target central to the HAE disease pathway, which is used in existing HAE treatments, including Shire’s injectable HAE drug Kalbitor®.

Verseon has developed a range of plasma kallikrein inhibitors using its computationally driven drug discovery platform. Many of these inhibitors have demonstrated good oral pharmacokinetic exposure, which is critical for convenient once-a-day oral dosing. In their interim report, Verseon presented data on a lead candidate that reduces swelling with efficacy comparable to a positive control in a carrageenan-induced paw edema model, a standard preclinical model for HAE.

Dr. David Kita, Vice President of R&D at Verseon, commented, “We are excited about the promising preclinical results for our hereditary angioedema candidates. We are continuing to optimize our drug candidates for oral bioavailability, efficacy, and safety to develop an effective and convenient treatment, which has the potential to change the standard of care for HAE patients.”

In the interim report, Verseon also presented substantial progress on its other drug programs. The Company is finalizing phase I preparations for the first development candidate in its anticoagulation program and has recently presented promising efficacy results in their diabetic macular edema program. A copy of the full interim report can be found here.

About Verseon

Verseon Corporation (, AIM: VSN) is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.

For further information please contact:
Verseon Corporation—Tina Schlafly
+1 (510) 225 9000
For trade and pharma media enquiries please contact:
Vane Percy & Roberts—Simon Vane Percy
+44 (0) 1737 821 890

Back to news